IP Library › Granted Patent US 12,329,756
Granted Patent B2
US 12,329,756 · App. 18/428,087 · Granted Jun 17, 2025

Regulation of eIF4E activity for migraine therapy

Inventors: Greg Dussor (Dallas, TX); Jacob E. Lackovic (Dallas, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
A61K31/506A61K31/05A61K31/167A61K31/19A61K31/343A61K31/426
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,756
App. No.
18/428,087
Granted
Jun 17, 2025
Kind
B2
Abstract

The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide, eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Claims (22)

1. A method of treating migraine in a human subject, comprising administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to treat said migraine.

2. The method of claim 1 , further comprising additionally administering to the subject a second therapeutic selected from cercosporamide, eFT508, 4EGI-1, a CGRP inhibitor, a gepant, lasmiditan, a triptan, an ergotamine, an antiemetic, a NSAID or a non-narcotic analgesic, an opiate analgesic, a non-opiate analgesic, a steroid, lidocaine, valproic acid, or propofol.

3. The method of claim 2 , wherein the first therapeutic and second therapeutic are co-formulated.

4. The method of claim 2 , wherein the first therapeutic and the second therapeutic are not co-formulated.

5. The method of claim 4 , wherein the first therapeutic and the second therapeutic are delivered at distinct times.

6. The method of claim 1 , wherein the first therapeutic is delivered daily.

7. The method of claim 1 , wherein the first therapeutic is delivered upon onset of at least one migraine symptom.

8. The method of claim 3 , wherein the first and second therapeutics are delivered daily.

9. The method of claim 3 , wherein the first and second therapeutics are delivered upon onset of at least one migraine symptom.

10. The method of claim 4 , wherein one of the first therapeutic or second therapeutic is delivered daily, while the other of the first therapeutic or second therapeutic is delivered upon onset of at least one migraine symptom.

11. The method of claim 4 , wherein the first therapeutic and second therapeutic are both delivered daily.

12. The method of claim 4 , wherein the first therapeutic and second therapeutic are both delivered upon onset of at least one migraine symptom.

13. The method of claim 1 , wherein the subject has previously experienced migraine.

14. A composition comprising:

at least two of cercosporamide, eFT508, or 4EGI-1, both in an effective amount to treat migraine in a human subject; and

a pharmaceutically acceptable carrier.

15. A composition comprising:

at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an effective amount to treat migraine in a human subject; and

a pharmaceutically acceptable carrier.

16. The method of claim 1 , wherein the first therapeutic is cercosporamide.

17. The method of claim 1 , wherein the first therapeutic is eFT508.

18. The method of claim 1 , wherein the first therapeutic is 4EGI-1.

Continuity (3)
Continuation 17495902 · Oct 7, 2021
Provisional Application 63089326 · Oct 8, 2020
Related Publication 20250017926A1 · Jan 16, 2025
References Cited (39)
US 11925642B2 · Dussor · 2024 [cited by examiner]
US 20150376181A1 · Reich et al. · 2015 [cited by applicant]
US 20200131179A1 · Reich et al. · 2020 [cited by applicant]
WO WO2017117052 · 2017 [cited by applicant]
WO WO2018218038 · 2018 [cited by applicant]
WO WO2020155842 · 2020 [cited by applicant]
Burgos-Vega, C. C. et al., “Non-invasive dural stimulation in mice: A novel preclinical model of migraine,” [cited by applicant]
Furukawa et al., “(−)-Cercosporamide derivatives as novel antihyperglycemic agents”, [cited by applicant]
Gkogkas et al (2013) Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 493 371 PMID: 23172145. [cited by applicant]
Harriott et al., “Animal models of migraine and experimental techniques used to examine trigeminal sensor processing”, [cited by applicant]
Hou., et al. “Targeting Mnks for cancer therapy”, [cited by applicant]
International Preliminary Report on Patentability for PCT/US2021/039982 dated Dec. 13, 2022, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US21/39982 dated Dec. 23, 2021, 11 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US22/35703 dated Nov. 16, 2022, 14 pages. [cited by applicant]
Jeevakumar et al., “IL-6 induced upregulation of T-type Ca [cited by applicant]
Khoutorsky et al., “Translational control of nociception via 4E-binding protein 1”, [cited by applicant]
Khoutorsky et al., “Translational control mechanisms in persistent pain”, [cited by applicant]
Konicek et al., “Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases”, [cited by applicant]
Lackovic et al “IHC 2019 Abstracts” received from https://journals.sagepub.com/doi/10.1177/0333102419859835, 2019. [cited by applicant]
Lackovic et al. “De novo protein synthesis is necessary for priming in preclinical models of migraine.” Poster—Society for Neuroscience, 2019. [cited by applicant]
Lackovic et al., “De novo protein synthesis is necessary for priming in preclinical models of migraine”, [cited by applicant]
Melemedjian et al., “IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex”, [cited by applicant]
Mitsikostas et al., “The 5-HT1F receptor as the target of ditans in migraine—from bench to bedside”, [cited by applicant]
Mody et al., “eIF4E phosphorylation modulates pain and neuroinflammation in the aged”, [cited by applicant]
Moerke et al., “Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G”, [cited by applicant]
Moy et al., “eIF4E phosphorylation influences Bdnf mRNA translation in mouse dorsal root ganglion neurons”, [cited by applicant]
Moy et al., “The MNKeIF4E signaling axis contributes to injury-induced nociceptive plasticity and the Development of chronic pain”, [cited by applicant]
Plessas et al., “Migraine-like Episodic Pain Behavior in a Dog: Can Dogs Suffer from Migraines?”, [cited by applicant]
Price et al., “Translation regulation and pain special issue editorial for neurobiology of pain”, [cited by applicant]
Price et al., “Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK”, [cited by applicant]
Price et al., Pharmacological manipulation of translation as a therapeutic target for chronic pain. [cited by applicant]
Pubchem CID 139317491, create date Nov. 2, 2019, date accessed Jul. 7, 2023, 10 pages. [cited by applicant]
Pubmed Compound Record for CID 118598717, ‘6-[(6-Aminopyrimidin-4-yl)amino]-3-(3-fluorophenyl)-3,8-dimethyl-2H-imidazo[1,5-a]pyridine-1,5-dione’, U.S. National Library of Medicine, Feb. 23, 2016, pp. 1-8. [cited by applicant]
Pubmed Compound Record for CID 144985837, ‘Tert-butyl N-[6-[(8-methyl-1, 5-dioxo-3,3-dipropyl-2H-imidazo(1,5-a]pyridine-6-yl)amino]pyrimidine-4-yl]carbamate’, U.S. National Library of Medicine, Dec. 7, 2019, pp. 1-6. [cited by applicant]
Rissardo et al., “Gepants for Acute and Preventive Migraine Treatment: A Narrative Review”, [cited by applicant]
Shukla et al., “A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice”, [cited by applicant]
Shiers et al., “Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK”, [cited by applicant]
Sussman et al., “Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening”, [cited by applicant]
Yousuf et al., “Pharmacological manipulation of translation as a therapeutic target for chronic pain”, [cited by applicant]